Alla Keyzner is an Oncology physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 86 publications with 539 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 100296030
Telephone
212-241-6756Registry record last updated 26 Feb 2019.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20258 payments
- Daiichi Sankyo Inc.Program year20253 payments
- GlaxoSmithKline, LLC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
21.9%Short-acting sulfonamides9.4%Sulfamethoxazole-Trimethoprim100%Part D≥19 patientsAzole Antifungal4.7%Posaconazole100%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
21.6%Bile Acid4.9%Ursodiol100%Part D≥13 patientsSerotonin-3 Receptor Antagonist4.3%Ondansetron Odt100%Part D<11 patients+ 5 more classes in this area
Cancer & immunology
18.1%Kinase inhibitor6%Jakafi66%Iclusig18%Sirolimus16%Part D<11 patientsCalcineurin inhibitor5.1%Tacrolimus100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation
Biology of Blood and Marrow Transplantation
2025 - TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)
Biology of Blood and Marrow Transplantation
2025 - Early de-escalation of empiric antibiotic therapy in neutropenic fever: a single-center, retrospective study
Antimicrobial Stewardship & Healthcare Epidemiology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”